In our previous research we developed highly conformal radiation treatment for head/neck and brain tumors usingsculpted dose distributions and demonstrated the ability to escalate tumor dose with minimal complications(brain), and maintain high control rates while decreasing a major complication (xerostomia) for head/neck cancers.Our long-term goal is to increase tumor control and reduce complication rates by individualizing the timing andintensity of therapy based on innovative imaging. We propose to intensify treatment for glioblastoma by escalatingthe daily fraction doses while also utilizing effective chemotherapy (temozolomide). We will test the hypothesisthat diffusion MRI (dMRI), which may predict tumor response early after therapy is started, will be a useful basisfor re-optimization during the course of treatment, allowing the escalation of dose to non-responding parts of thetumor. We will also make use of our preliminary MRI results which suggest that radiation can open the bloodtumor-barrier (BTB) to chemotherapeutic and radiosensitizing agents (like gemitabine). We will test whetherconcurrent conformal radiation and gemcitabine (administered after the BTB is opened) will be safer and improveresponse rates for grade 3 gliomas, and whether we can improve the outcome by escalating the doses to the parts ofthe tumor demonstrating lack of increased permeability of the BTB early after the start of therapy. In head andneck cancer, we will test strategies that promise to decrease treatment-related late dysphagia and aspiration. Wewill test if reducing dose to the swallowing structures can reduce the severity of late dysphagia, and test the utility ofinnovative imaging (FLT-PET, and dMRI) to predict (early after the start of therapy) which tumors are likely to failtreatment, as well as directing individualized dose intensification using re-optimization plans. We expect thatthe Project will show improving non-complicated tumor control rates in brain and head and neck cancer bycustomizing treatment intensity following analysis of possible early predictors of response.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA059827-11A1
Application #
7082533
Study Section
Subcommittee G - Education (NCI)
Project Start
2006-04-01
Project End
2011-06-30
Budget Start
2006-04-01
Budget End
2007-06-30
Support Year
11
Fiscal Year
2006
Total Cost
$222,196
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Ohri, Nitin; Tomé, Wolfgang A; Méndez Romero, Alejandra et al. (2018) Local Control After Stereotactic Body Radiation Therapy for Liver Tumors. Int J Radiat Oncol Biol Phys :
Mendiratta-Lala, Mishal; Gu, Everett; Owen, Dawn et al. (2018) Imaging Findings Within the First 12 Months of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 102:1063-1069
Wang, Shulian; Campbell, Jeff; Stenmark, Matthew H et al. (2018) A model combining age, equivalent uniform dose and IL-8 may predict radiation esophagitis in patients with non-small cell lung cancer. Radiother Oncol 126:506-510
Sapir, Eli; Tao, Yebin; Schipper, Matthew J et al. (2018) Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 100:122-130
Hawkins, Peter G; Boonstra, Philip S; Hobson, Stephen T et al. (2018) Prediction of Radiation Esophagitis in Non-Small Cell Lung Cancer Using Clinical Factors, Dosimetric Parameters, and Pretreatment Cytokine Levels. Transl Oncol 11:102-108
Sun, Yilun; Hawkins, Peter G; Bi, Nan et al. (2018) Serum MicroRNA Signature Predicts Response to High-Dose Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 100:107-114
Kong, Feng-Ming Spring; Li, Ling; Wang, Weili et al. (2018) Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer. Radiother Oncol :
Shilkrut, Mark; Sapir, Eli; Hanasoge, Sheela et al. (2018) Phase I Trial of Dose-escalated Whole Liver Irradiation With Hepatic Arterial Fluorodeoxyuridine/Leucovorin and Streptozotocin Followed by Fluorodeoxyuridine/Leucovorin and Chemoembolization for Patients With Neuroendocrine Hepatic Metastases. Am J Clin Oncol 41:326-331
Jackson, William C; Tao, Yebin; Mendiratta-Lala, Mishal et al. (2018) Comparison of Stereotactic Body Radiation Therapy and Radiofrequency Ablation in the Treatment of Intrahepatic Metastases. Int J Radiat Oncol Biol Phys 100:950-958
Miften, Moyed; Vinogradskiy, Yevgeniy; Moiseenko, Vitali et al. (2018) Radiation Dose-Volume Effects for Liver SBRT. Int J Radiat Oncol Biol Phys :

Showing the most recent 10 out of 289 publications